DaVita (NYSE:DVA) Issues FY 2024 Earnings Guidance

DaVita (NYSE:DVA) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided EPS guidance of 9.000-9.800 for the period, compared to the consensus EPS estimate of 9.010. The company issued revenue guidance of -.

DaVita Trading Up 1.8 %

NYSE:DVA traded up $2.42 on Monday, hitting $136.87. The stock had a trading volume of 1,433,893 shares, compared to its average volume of 846,295. The company has a quick ratio of 1.37, a current ratio of 1.43 and a debt-to-equity ratio of 7.95. The stock has a market cap of $12.00 billion, a price-to-earnings ratio of 15.49, a PEG ratio of 1.17 and a beta of 1.04. The company has a fifty day moving average price of $133.71 and a two-hundred day moving average price of $113.08. DaVita has a 1-year low of $71.51 and a 1-year high of $145.04.

DaVita (NYSE:DVA) last posted its earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, beating the consensus estimate of $1.95 by $0.43. The company had revenue of $3.07 billion for the quarter, compared to analyst estimates of $3.03 billion. DaVita had a net margin of 6.61% and a return on equity of 68.52%. DaVita’s revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.58 EPS. Equities research analysts expect that DaVita will post 9.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on DVA. StockNews.com raised shares of DaVita from a buy rating to a strong-buy rating in a research note on Thursday, April 25th. Truist Financial boosted their price target on shares of DaVita from $130.00 to $135.00 and gave the company a hold rating in a research note on Tuesday, February 20th. Barclays boosted their price target on shares of DaVita from $133.00 to $150.00 and gave the company an equal weight rating in a research note on Monday. UBS Group upped their target price on shares of DaVita from $113.00 to $134.00 and gave the stock a buy rating in a research note on Wednesday, February 14th. Finally, TheStreet raised shares of DaVita from a c+ rating to a b- rating in a research note on Wednesday, February 7th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average target price of $121.33.

Insider Buying and Selling at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 11,285 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $120.73, for a total value of $1,362,438.05. Following the sale, the insider now directly owns 81,297 shares of the company’s stock, valued at approximately $9,814,986.81. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the transaction, the chief executive officer now owns 488,697 shares in the company, valued at approximately $61,629,578.67. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Kathleen Alyce Waters sold 11,285 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $120.73, for a total transaction of $1,362,438.05. Following the completion of the transaction, the insider now owns 81,297 shares of the company’s stock, valued at approximately $9,814,986.81. The disclosure for this sale can be found here. In the last three months, insiders have sold 134,540 shares of company stock valued at $16,551,071. Insiders own 1.40% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.